blue cross blue shield glp 1 of Massachusetts will stop covering popular GLP-1 weight-loss drugs like Ozempic and Wegovy starting January 1, 2026. The decision comes as the costs for these medications have Independence Blue Cross to stop
Description
Chicory inulin
We did not identify a statistically significant increase in stroke risk among GLP-1RA users compared to SGLT2 users
But they more effectively lower fasting glucose and overall glycemia
I think that potential is there for positive impact, but there are not enough studies yet. Novo Nordisk, which makes Wegovy, doesnt encourage off-label use of its obesity medications
Consult qualified medical professionals for personalized guidance
What is Mounjaro (Tirzepatide)
